Silexion Therapeutics (NASDAQ:SLXN) Coverage Initiated by Analysts at Litchfield Hills Research

Stock analysts at Litchfield Hills Research started coverage on shares of Silexion Therapeutics (NASDAQ:SLXN) in a report released on Monday, Marketbeat.com reports. The brokerage set a “buy” rating on the stock. Litchfield Hills Research also issued estimates for Silexion Therapeutics’ Q4 2025 earnings at ($1.17) EPS, FY2025 earnings at ($3.83) EPS and FY2026 earnings at ($4.80) EPS.

A number of other brokerages have also commented on SLXN. Wall Street Zen upgraded Silexion Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $75.00.

Silexion Therapeutics Price Performance

SLXN traded down $0.05 during trading on Monday, hitting $2.52. The company’s stock had a trading volume of 13,686 shares, compared to its average volume of 411,396. The company has a quick ratio of 3.97, a current ratio of 3.97 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $7.89 million, a price-to-earnings ratio of -0.23 and a beta of -0.06. The firm’s 50 day moving average price is $3.04 and its two-hundred day moving average price is $6.95. Silexion Therapeutics has a 12 month low of $2.13 and a 12 month high of $51.75.

Silexion Therapeutics (NASDAQ:SLXN) last announced its earnings results on Wednesday, November 12th. The company reported ($2.88) EPS for the quarter, topping the consensus estimate of ($3.40) by $0.52.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.